Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Lung Cancer

  Free Subscription


14.10.2019

7 Ann Thorac Surg
3 Anticancer Res
1 BMJ
1 Cancer Lett
2 Cancer Res
1 Cancer Sci
1 Chest
1 Clin Cancer Res
1 Clin Lung Cancer
3 Int J Cancer
4 Int J Radiat Oncol Biol Phys
2 J Cancer Res Clin Oncol
2 J Thorac Cardiovasc Surg
2 Lancet
3 Lancet Oncol
4 Lung Cancer
2 Nat Med
1 Oncogene
1 PLoS Genet
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Thorac Surg

  1. SULIBHAVI A, Asokan S, Miller MI, Moreira P, et al
    Peripheral blood lymphocytes and platelets are prognostic in surgical pT1 non-small cell lung cancer.
    Ann Thorac Surg. 2019 Oct 5. pii: S0003-4975(19)31551.
    PubMed     Text format     Abstract available

  2. SATO M, Nagayama K, Kobayashi M, Nakajima J, et al
    Virtual-Assisted Lung Mapping 2.0: Preoperative Bronchoscopic Three-Dimensional Lung Mapping.
    Ann Thorac Surg. 2019;108:269-273.
    PubMed     Text format     Abstract available

  3. MIYOSHI T, Aokage K, Katsumata S, Tane K, et al
    Ground-Glass Opacity Is a Strong Prognosticator for Pathologic Stage IA Lung Adenocarcinoma.
    Ann Thorac Surg. 2019;108:249-255.
    PubMed     Text format     Abstract available

  4. ZHANG XM, Fournel L, Lupo A, Canny E, et al
    En Bloc Resection of Thoracic Tumors Invading the Spine: A Single-Center Experience.
    Ann Thorac Surg. 2019;108:227-234.
    PubMed     Text format     Abstract available

  5. JIAO W, Zhao Y, Qiu T, Xuan Y, et al
    Robotic Bronchial Sleeve Lobectomy for Central Lung Tumors: Technique and Outcome.
    Ann Thorac Surg. 2019;108:211-218.
    PubMed     Text format     Abstract available

  6. SHIMIZU K, Goto Y, Kawabata-Iwakawa R, Ohtaki Y, et al
    Stathmin-1 Is a Useful Diagnostic Marker for High-Grade Lung Neuroendocrine Tumors.
    Ann Thorac Surg. 2019;108:235-243.
    PubMed     Text format     Abstract available

  7. BECKERS PAJ, Versteegh MIM, Van Brakel TJ, Braun J, et al
    Multicenter Phase II Clinical Trial of Isolated Lung Perfusion in Patients With Lung Metastases.
    Ann Thorac Surg. 2019;108:167-174.
    PubMed     Text format     Abstract available


    Anticancer Res

  8. NAKANISHI K, Sakakura N, Matsui T, Ueno H, et al
    Clinicopathological Features, Surgical Outcomes, Oncogenic Status and PD-L1 Expression of Pulmonary Pleomorphic Carcinoma.
    Anticancer Res. 2019;39:5789-5795.
    PubMed     Text format     Abstract available

  9. REYNEL M, Villegas Y, Kiene H, Werthmann PG, et al
    Bilateral Asynchronous Renal Cell Carcinoma With Lung Metastases: A Case Report of a Patient Treated Solely With High-dose Intravenous and Subcutaneous Viscum album Extract for a Second Renal Lesion.
    Anticancer Res. 2019;39:5597-5604.
    PubMed     Text format     Abstract available

  10. ALTURKISTANI A, Ghonem N, Power-Charnitsky VA, Pino-Figueroa A, et al
    Inhibition of PAR-1 Receptor Signaling by Enoxaparin Reduces Cell Proliferation and Migration in A549 Cells.
    Anticancer Res. 2019;39:5297-5310.
    PubMed     Text format     Abstract available


    BMJ

  11. ZHAO Y, Liu J, Cai X, Pan Z, et al
    Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis.
    BMJ. 2019;367:l5460.
    PubMed     Text format     Abstract available


    Cancer Lett

  12. YANG D, Liu Y, Bai C, Wang X, et al
    Epidemiology of lung cancer and lung cancer screening program in China and the United States.
    Cancer Lett. 2019 Oct 7. pii: S0304-3835(19)30500.
    PubMed     Text format     Abstract available


    Cancer Res

  13. MERRICK DT
    Sequencing the Events That Mediate Progression of Premalignant Lung Lesions.
    Cancer Res. 2019;79:4811-4813.
    PubMed     Text format     Abstract available

  14. KRYSAN K, Tran LM, Grimes BS, Fishbein GA, et al
    The Immune Contexture Associates with the Genomic Landscape in Lung Adenomatous Premalignancy.
    Cancer Res. 2019;79:5022-5033.
    PubMed     Text format     Abstract available


    Cancer Sci

  15. GONG R, Lin W, Gao A, Liu Y, et al
    Forkhead box C1 promotes metastasis and invasion of non-small cell lung cancer by binding directly to the lysyl oxidase promoter.
    Cancer Sci. 2019 Oct 9. doi: 10.1111/cas.14213.
    PubMed     Text format     Abstract available


    Chest

  16. VELUSWAMY RR, Whittaker Brown SA, Mhango G, Sigel K, et al
    Comparative Effectiveness of Robotic-Assisted Surgery for Resectable Lung Cancer in Older Patients.
    Chest. 2019 Oct 4. pii: S0012-3692(19)33946-7. doi: 10.1016/j.chest.2019.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  17. RECONDO G, Mezquita L, Facchinetti F, Planchard D, et al
    Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer.
    Clin Cancer Res. 2019 Oct 4. pii: 1078-0432.CCR-19-1104.
    PubMed     Text format     Abstract available


    Clin Lung Cancer

  18. WU GX, Ituarte PHG, Ferrell B, Sun V, et al
    Causes of Death and Hospitalization in Long-term Lung Cancer Survivors: A Population-based Appraisal.
    Clin Lung Cancer. 2019 Aug 30. pii: S1525-7304(19)30256.
    PubMed     Text format     Abstract available


    Int J Cancer

  19. GE Q, Lu M, Ju L, Qian K, et al
    miR-4324-RACGAP1-STAT3-ESR1 feedback loop inhibits proliferation and metastasis of bladder cancer.
    Int J Cancer. 2018 Dec 3. doi: 10.1002/ijc.32036.
    PubMed     Text format     Abstract available

  20. QIAN J, Nie W, Lu J, Zhang L, et al
    Racial differences in characteristics and prognoses between Asian and white patients with non-small cell lung cancer receiving atezolizumab: an ancillary analysis of the POPLAR and OAK studies.
    Int J Cancer. 2019 Oct 3. doi: 10.1002/ijc.32717.
    PubMed     Text format     Abstract available

  21. STAPELFELD C, Dammann C, Maser E
    Sex-specificity in lung cancer risk.
    Int J Cancer. 2019 Oct 3. doi: 10.1002/ijc.32716.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  22. LARSEN F, Terlizzi M, Linacre V, Sargos P, et al
    Radiation Therapy in Resectable Intrathoracic Sarcomas. A Rare Cancer Network Study.
    Int J Radiat Oncol Biol Phys. 2019;103:1175-1181.
    PubMed     Text format     Abstract available

  23. GASPAR LE
    A Gray Zone Regarding Gray Matter.
    Int J Radiat Oncol Biol Phys. 2019;103:1033-1034.
    PubMed     Text format    

  24. KANG J, Ning MS, Feng H, Li H, et al
    Predicting 5-Year Progression and Survival Outcomes for Early-Stage Non-Small Cell Lung Cancer Treated with Stereotactic Ablative Radiotherapy: Development and Validation of Robust Prognostic Nomograms.
    Int J Radiat Oncol Biol Phys. 2019 Oct 3. pii: S0360-3016(19)33861.
    PubMed     Text format     Abstract available

  25. WEGNER RE, Hasan S
    Observe the Brain and Preserve the Mind.
    Int J Radiat Oncol Biol Phys. 2019;103:1033.
    PubMed     Text format    


    J Cancer Res Clin Oncol

  26. NI Y, Ye X, Yang X, Huang G, et al
    Microwave ablation as local consolidative therapy for patients with extracranial oligometastatic EGFR-mutant non-small cell lung cancer without progression after first-line EGFR-TKIs treatment.
    J Cancer Res Clin Oncol. 2019 Oct 10. pii: 10.1007/s00432-019-03043.
    PubMed     Text format     Abstract available

  27. DENG LL, Gao G, Deng HB, Wang F, et al
    Co-occurring genetic alterations predict distant metastasis and poor efficacy of first-line EGFR-TKIs in EGFR-mutant NSCLC.
    J Cancer Res Clin Oncol. 2019;145:2613-2624.
    PubMed     Text format     Abstract available


    J Thorac Cardiovasc Surg

  28. YAMAMICHI T, Shimada Y, Masuno R, Ohira T, et al
    Association between F-18 fluorodeoxyglucose uptake of noncancerous lung area and acute exacerbation of interstitial pneumonia in patients with lung cancer after resection.
    J Thorac Cardiovasc Surg. 2019 Aug 28. pii: S0022-5223(19)31659.
    PubMed     Text format     Abstract available

  29. JIANG L, Huang W, Liu J, Harris K, et al
    Endosonography with lymph node sampling for restaging the mediastinum in lung cancer: A systematic review and pooled data analysis.
    J Thorac Cardiovasc Surg. 2019 Aug 28. pii: S0022-5223(19)31649.
    PubMed     Text format     Abstract available


    Lancet

  30. PAZ-ARES L, Dvorkin M, Chen Y, Reinmuth N, et al
    Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
    Lancet. 2019 Oct 4. pii: S0140-6736(19)32222.
    PubMed     Text format     Abstract available

  31. GOETZE TO
    Immunotherapy: a new era in small-cell lung cancer.
    Lancet. 2019 Oct 4. pii: S0140-6736(19)32235.
    PubMed     Text format    


    Lancet Oncol

  32. AHN MJ, Han JY, Lee KH, Kim SW, et al
    Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study.
    Lancet Oncol. 2019 Oct 3. pii: S1470-2045(19)30504.
    PubMed     Text format     Abstract available

  33. ROSELL R, Pedraz-Valdunciel C
    Are neutralising anti-VEGF or VEGFR2 antibodies necessary in the treatment of EGFR-mutated non-small-cell lung cancer?
    Lancet Oncol. 2019 Oct 4. pii: S1470-2045(19)30636.
    PubMed     Text format    

  34. NAKAGAWA K, Garon EB, Seto T, Nishio M, et al
    Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2019 Oct 4. pii: S1470-2045(19)30634.
    PubMed     Text format     Abstract available


    Lung Cancer

  35. MEHLMAN C, Cadranel J, Rousseau-Bussac G, Lacave R, et al
    Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study.
    Lung Cancer. 2019;137:149-156.
    PubMed     Text format     Abstract available

  36. BESSE B, Barlesi F, Demedts I, Fuentes Pradera J, et al
    A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer.
    Lung Cancer. 2019;137:136-143.
    PubMed     Text format     Abstract available

  37. PARK SY, Byun GE, Lee CY, Lee JG, et al
    Clinical implications of uncertain resection in scenarios of metastasis of the highest or most distant mediastinal lymph node station following surgical treatment of non-small-cell lung cancer.
    Lung Cancer. 2019;138:1-5.
    PubMed     Text format     Abstract available

  38. AGER BJ, Wells SM, Gruhl JD, Stoddard GJ, et al
    Stereotactic body radiotherapy versus percutaneous local tumor ablation for early-stage non-small cell lung cancer.
    Lung Cancer. 2019;138:6-12.
    PubMed     Text format     Abstract available


    Nat Med

  39. JOSHI K, Robert de Massy M, Ismail M, Reading JL, et al
    Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer.
    Nat Med. 2019 Oct 4. pii: 10.1038/s41591-019-0592.
    PubMed     Text format     Abstract available

  40. BISWAS D, Birkbak NJ, Rosenthal R, Hiley CT, et al
    A clonal expression biomarker associates with lung cancer mortality.
    Nat Med. 2019 Oct 7. pii: 10.1038/s41591-019-0595.
    PubMed     Text format     Abstract available


    Oncogene

  41. SHIN SB, Jang HR, Xu R, Won JY, et al
    Correction: Active PLK1-driven metastasis is amplified by TGF-beta signaling that forms a positive feedback loop in non-small cell lung cancer.
    Oncogene. 2019 Oct 8. pii: 10.1038/s41388-019-1049.
    PubMed     Text format     Abstract available


    PLoS Genet

  42. MALVI P, Janostiak R, Nagarajan A, Cai G, et al
    Loss of thymidine kinase 1 inhibits lung cancer growth and metastatic attributes by reducing GDF15 expression.
    PLoS Genet. 2019;15:e1008439.
    PubMed     Text format     Abstract available


    PLoS One

  43. LU S, Dong Z
    Additive effects of a small molecular PCNA inhibitor PCNA-I1S and DNA damaging agents on growth inhibition and DNA damage in prostate and lung cancer cells.
    PLoS One. 2019;14:e0223894.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: